Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000102909-26-000090·ArriVent BioPharma, Inc.
Schedule 13G ownership disclosure
ArriVent Biopharma Inc
Common Stock · CUSIP: 04272N102
Event date: 2025-12-31
- Filing-level shares
- 1,869,266
- Percent of class
- 4.52%
- The Vanguard Group
Shares: 1,869,266 · Class: 4.52%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-26-000090
- Form type
- SCHEDULE 13G/A
- Filer
- ArriVent BioPharma, Inc.
- CIK
- CIK 1868279
- Filed
- Jan 30, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership